Geode Capital Management
CLRB icon

Geode Capital Management’s Cellectar Biosciences CLRB Stock Holding History

Geode Capital Management’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$148K Buy
53,351
+573
+1% +$1.6K ﹤0.01% 4007
2026
Q1 		$134K Buy
52,778
+24,142
+84% +$77.9K ﹤0.01% 4055
2025
Q4 		$84.5K Buy
28,636
+3,744
+15% +$13.8K ﹤0.01% 4134
2025
Q3 		$139K Buy
24,892
+10,453
+72% +$51.8K ﹤0.01% 4038
2025
Q2 		$103K Sell
14,439
-342
-2% -$2.99K ﹤0.01% 4053
2025
Q1 		$140K Buy
14,781
+3,085
+26% +$27.9K ﹤0.01% 3941
2024
Q4 		$105K Sell
11,696
-52
-0.4% -$2.4K ﹤0.01% 4087
2024
Q3 		$754K Buy
11,748
+375
+3% +$24.7K ﹤0.01% 3457
2024
Q2 		$853K Buy
11,373
+837
+8% +$80.3K ﹤0.01% 3371
2024
Q1 		$1.26M Buy
10,536
+8,240
+359% +$893K ﹤0.01% 3274
2023
Q4 		$191K Buy
2,296
+201
+10% +$15K ﹤0.01% 3957
2023
Q3 		$166K Buy
2,095
+533
+34% +$31.4K ﹤0.01% 4052
2023
Q2 		$91.4K Sell
1,562
-13
-0.8% -$626 ﹤0.01% 4364
2023
Q1 		$68K Sell
1,575
-26
-2% -$1.27K ﹤0.01% 4451
2022
Q4 		$82K Buy
1,601
+120
+8% +$7.19K ﹤0.01% 4458
2022
Q3 		$149K Hold
1,481
– – ﹤0.01% 4368
2022
Q2 		$179K Buy
1,481
+8
+0.5% +$1.14K ﹤0.01% 4338
2022
Q1 		$303K Hold
1,473
– – ﹤0.01% 4179
2021
Q4 		$293K Hold
1,473
– – ﹤0.01% 4301
2021
Q3 		$408K Buy
1,473
+149
+11% +$45.5K ﹤0.01% 4130
2021
Q2 		$472K Buy
1,324
+509
+62% +$221K ﹤0.01% 3968
2021
Q1 		$393K Buy
815
+374
+85% +$222K ﹤0.01% 3888
2020
Q4 		$275K Buy
+441
New +$203K ﹤0.01% 3788
2018
Q3 		– Sell
-24
Closed -$44K – 4127
2018
Q2 		$44K Buy
+24
New +$73.7K ﹤0.01% 3987
2016
Q1 		– Sell
-1
Closed -$33K – 4100
2015
Q4 		$33K Hold
1
– – ﹤0.01% 4055
2015
Q3 		$88K Buy
+1
New +$91K ﹤0.01% 3924

Other funds holding CLRB

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return

Geode Capital Management's CLRB Position: Q2 2026 in Review

Geode Capital Management increased its Cellectar Biosciences (CLRB) stake by 1.1% in Q2 2026, buying an estimated $1.6K and bringing the position to 53,351 shares worth $148K. The position accounts for ﹤0.01% of the portfolio, ranked #4007.

Geode Capital Management first reported a position in CLRB in Q3 2015 and has held it in 26 quarters since. The position peaked at $1.26M in Q1 2024. 29 funds tracked by Wall St. Rank hold CLRB as of Q2 2026.

  • Geode Capital Management held 53,351 shares of Cellectar Biosciences worth $148K as of Q2 2026.
  • Geode Capital Management bought 573 Cellectar Biosciences shares in Q2 2026, an estimated $1.6K.
  • Cellectar Biosciences made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #4007 holding.
  • Geode Capital Management first reported a position in Cellectar Biosciences in Q3 2015 and has held it in 26 quarters since.
  • Geode Capital Management's Cellectar Biosciences position peaked at $1.26M in Q1 2024.
  • 29 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.